Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50–60% of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4% in the omega-3 fatty acid group and 45.5% in the placebo group showing 50% or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months. TRIAL REGISTRATION: ClinicalTrials.gov NCT00122954.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Mohr, D. C., Boudewyn, A. C., Goodkin, D. E., Bostrom, A., & Epstein, L. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.6.942 · Cited by 334 · cited 1×
“The Beck Depression Inventory, version 1 (BDI-I) is a self-report measure of depression and is commonly used in MS studies because it is an easily administered depression measure [13,17].”
MethodSelf-citationMüller, M. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00120-9 · Cited by 282
Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f3b5f · Cited by 162
Cited by
Efficacy of omega-3 PUFAs in depression: A meta-analysis
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0515-5 · Cited by 404
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
Dang, R., Zhou, X., Tang, M., Xu, P., Gong, X., Liu, Y., Jiao, H., & Jiang, P. (2018) · European Journal of Nutrition · doi:10.1007/s00394-016-1373-z · Cited by 93
Omega-3 fatty acids for depression in adults
Appleton, K. M., Voyias, P. D., Sallis, H. M., Dawson, S., Ness, A. R., Churchill, R., & Perry, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub5 · Cited by 84
Kamat, D., Al-Ajlouni, Y. A., & Hall, R. C. W. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20065171 · Cited by 10
Metadata
- Authors
- Shinto, L., Marracci, G., Mohr, D. C., Bumgarner, L., Murchison, C., Senders, A., & Bourdette, D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-22
- Volume
- 11
- Issue
- 1
- Pages
- e0147195
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2262147207
- Cited by
- 46
- References
- 8
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.